In this article, we will look at July’s top 10 traded US stocks on Singapore’s Phillip’s Online Electronic Mart System (POEMS), based on their gross market values traded. We hope this data will bring you some useful insights in terms of liquidity, consumer trend and a quick overall macroeconomic view that are affecting these popular traded stocks.
We saw a steady rise in 3 US major indexes: Dow Jones, S&P 500 and NASDAQ in early July, which retraced slightly before moving sideways in the second half of July. Many of the tech stocks hit a new all-time high as well during that period. Precious metals, Gold and Silver outperformed the market in late July as Central Banks around the world continue to work on more stimulus plans.
Without further ado, let’s count down the top 10 list:
10th: Fastly Inc (NYSE: FSLY)
At the 10th position is Fastly, a provider of edge cloud computing and content delivery network (CDN). Cloud computing has been outperforming the market extremely well due to various restrictions implemented amid the COVID-19 pandemic. Fastly shares doubled in June and went on to hit its all-time high at USD 102.95 on 9 July, about 10 folds from market bottom in March.
While this is a promising and growing industry, Fastly is relatively a smaller-scale company as compared to its much larger and well-known rivals. There is still much room for Fastly to work on and further its growth.
9th: Sorrento Therapeutics Inc. (NASDAQ: SRNE)
One of the key players in developing vaccine and treatment to counter the COVID-19 virus, Sorrento Therapeutics claimed the 9th spot. Its share price jumped 24.4% in June and spiked further after announcing the positive results achieved in its preclinical data of vaccine in the first week of July.
While the preclinical data is encouraging, Sorrento is lacking behind some of its competitors which are already at their later stage of clinical trial in vaccine developments. If these rivals are able to complete the trial stage and make it to the market at the right time, Sorrento will likely be left out of the race. Nevertheless, volatility is expected to continue among the bio tech companies as the vaccine race will go on for a period of time.
8th: Amazon.com Inc (NASDAQ: AMZN)
The trillion-dollar company and tech giant, Amazon, is the 8th top traded stocks on POEMS in July. Amazon made it to the list as the stock crossed the USD 3,000 mark for the first time on 6 July and hitting a new all-time high on 13th July at USD 3344.29.
With the strong growth in e-commerce space despite the COVID-19 pandemic, Amazon is aggressively restructuring its operation by automating its processes. For example, it is diligently expanding the use of its Scout robot in new locations for the last mile delivery.
Besides, Amazon India is currently in talks to acquire a strategic stake in Reliance retail arm in India. JioMart, the e-commerce venture of Reliance which is controlled by Asia’s richest man, Mukesh Ambani was launched in May to challenge Amazon and Walmart’s Flipkart.1
7th: Facebook Inc (NASDAQ: FB)
Dropping from the 6th position in the previous month, Facebook claimed the 7th spot on the list in July. Facebook does not seem to have been impacted much from the hate speech campaign that happened towards the end of June. Its share price recovered to hit an all-time high of USD 250.15 on 13 July.
In addition to the advertisement boycott, Facebook has been involved in multiple privacy lawsuits and antitrust investigation. The EU antitrust probe is temporarily halted as Facebook claimed that the data requested had invaded its employees’ privacy. Together with Facebook, Amazon, Apple and Google, the big 4 tech firms’ executives in the United States testified before congress on 29 July that their businesses did not stifle competition.2
6th: Alibaba Group Holding Ltd (NYSE: BABA)
Similar to Facebook, Alibaba slipped to 6th top traded counter from 5th position in the previous month. As one of the largest tech companies in the world, Alibaba also hit its all-time high at USD 268 on 9 July.
Intense uncertainty remains due to the COVID-19 pandemic and Alibaba’s chairman’s emphasis of digitalisation as the new norm in his letter to its shareholders. The key focus of the company is to drill towards the development of digital solutions in various areas such as work, education, daily life or even public services. As what Microsoft did before, Alibaba will also be looking into cloud computing as the company’s new growth engine and to power its digital economy.3
5th: Boeing Co (NYSE: BA)
The month of July has seen the commercial aerospace giant drop from the top spot in June to become the fifth-most traded stock on POEMS. The global drop in demand for commercial jets could see Boeing’s new flagship, the 777X push back to 2022.4
However, the company’s defence, space and security business segments managed to secure several multimillion dollar contracts to deliver defence and weapon systems to the Saudi Arabian and Moroccan army during the second quarter of 2020. The business unit has also been witnessing consistent order flow from the Pentagon, NASA and Congress for its varied products5.
The defence-related revenue sources amount to about 20% of Boeing sales in a non-pandemic year and may help soften the adverse impact caused by the severe decline in air travel.
4th: Moderna Inc. (NASDAQ: MRNA)
Moderna maintained its fourth position for top traded stock on POEMS in July. The biotech company announced the start of the final clinical trial phase of its much anticipated COVID-19 vaccine candidate (mRNA-1273) on 27 July 2020. Without a safe and effective vaccine, the world simply cannot control this pandemic and return to normalcy.
Moderna has already received more than US$1 billion from the US government in a bid to develop the vaccine in record time and the vaccine could be available for widespread use by the end of this year.7
3rd: NIO Inc (NYSE: NIO)
The month of July saw a surprise candidate occupying the third place for the top traded stocks on POEMS. Chinese premium electric vehicle start-up, NIO, has seen its share price rally by about 50% after beating Wall Street’s quarterly delivery forecast and an increased demand for stocks of electric vehicle companies due to Tesla’s share performance.8
Nonetheless, the rising US – China tensions could have implications across the overall economy and result in weakness in the equity market, especially for Chinese companies.
2nd: Microsoft Corporation (NASDAQ: MSFT)
Another trillion-dollar company and tech giant, Microsoft crawled its way up to the second spot in July after missing the top ten placing in June. Microsoft’s successful transition into cloud computing has placed the company in a good position to grow over the long term. The scheduled launch of the Xbox Series X in the holiday season of 2020 will also provide a buffer to Microsoft’s revenue growth.
However, the COVID-19 pandemic had a detrimental effect on some of Microsoft’s business units during the last quarter. Given the weak job market, the social network LinkedIn laid off 960 employees or 6% of its global workforce.9
1st: Tesla Inc (NASDAQ: TSLA)
The meteoric rise of Tesla Inc’s share price continued as it overtook Boeing Co (NYSE: BA) to become the top traded stock on POEMS in July. The electric car maker is looking to expand its operations in China by launching a mass recruitment drive to prepare for the manufacturing of its Model Y vehicle.
In addition, Tesla is also planning to establish a research and design centre in China to produce “Chinese-style” cars in order to dominate the world’s largest electric vehicle market.10
-  https://www.reuters.com/article/us-reliance-amazon-com-stake-idUSKCN24O1BP
-  https://www.cnet.com/news/how-to-watch-apple-amazon-google-facebook-ceos-to-testify-to-congress/
-  https://www.alibabagroup.com/en/news/article?news=p200709a
-  https://www.foxbusiness.com/markets/boeing-to-delay-777x-as-demand-drops-for-big-jets-sources
-  https://finance.yahoo.com/news/defense-deliveries-drive-boeings-ba-145802975.html
-  https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins
-  https://www.channelnewsasia.com/news/world/moderna-covid-19-vaccine-ready-use-us-12967246
-  https://www.nasdaq.com/articles/nio-could-head-lower-but-be-careful-going-short-2020-07-24
-  https://www.straitstimes.com/business/companies-markets/linkedin-cuts-960-jobs-as-pandemic-puts-the-brakes-on-corporate-hiring
-  https://www.benzinga.com/news/20/07/16800356/tesla-on-a-hiring-spree-in-china-as-it-readies-for-model-y-production-report
Important Information: This report is prepared and/or distributed by Phillip Securities Research Pte Ltd (“Phillip Securities Research”), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgement. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSES Where the report contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact Phillip Securities Research (and not the relevant foreign research house) in Singapore at 250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101, telephone number +65 6533 6001, in respect of any matters arising from, or in connection with, the analyses or reports; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, Phillip Securities Research accepts legal responsibility for the contents of the analyses or reports.
If Distribution is to Australian Investors This report is produced by Phillip Securities Pte Ltd and is being distributed in Australia by Phillip Capital Limited (Australian Financial Services License No. 246827). This report contains general securities advice and does not take into account your personal objectives, situation and needs. Please read the Disclosures and Disclaimers set out above. By receiving or reading this report, you agree to be bound by the terms and limitations set out above. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.